NF-kappa B pathways in the pathogenesis of multiple sclerosis and the therapeutic implications

Leibowitz, Saskia M. and Yan, Jun (2016) NF-kappa B pathways in the pathogenesis of multiple sclerosis and the therapeutic implications. Frontiers in Molecular Neuroscience, 9 84: . doi:10.3389/fnmol.2016.00084


Author Leibowitz, Saskia M.
Yan, Jun
Title NF-kappa B pathways in the pathogenesis of multiple sclerosis and the therapeutic implications
Formatted title
NF-κB pathways in the pathogenesis of multiple sclerosis and the therapeutic implications
Journal name Frontiers in Molecular Neuroscience   Check publisher's open access policy
ISSN 1662-5099
Publication date 2016-09-15
Year available 2016
Sub-type Critical review of research, literature review, critical commentary
DOI 10.3389/fnmol.2016.00084
Open Access Status DOI
Volume 9
Issue 84
Total pages 23
Place of publication Lausanne, Switzerland
Publisher Frontiers Research Foundation
Collection year 2017
Language eng
Formatted abstract
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways are involved in cell immune responses, apoptosis and infections. In multiple sclerosis (MS), NF-κB pathways are changed, leading to increased levels of NF-κB activation in cells. This may indicate a key role for NF-κB in MS pathogenesis. NF-κB signaling is complex, with many elements involved in its activation and regulation. Interestingly, current MS treatments are found to be directly or indirectly linked to NF-κB pathways and act to adjust the innate and adaptive immune system in patients. In this review, we will first focus on the intricacies of NF-κB signaling, including the activating pathways and regulatory elements. Next, we will theorize about the role of NF-κB in MS pathogenesis, based on current research findings, and discuss some of the associated therapeutic implications. Lastly, we will review four new MS treatments which interrupt NF-κB pathways—fingolimod, teriflunomide, dimethyl fumarate (DMF) and laquinimod (LAQ)—and explain their mechanisms, and the possible strategy for MS treatments in the future.
Keyword NF-κB
Multiple sclerosis
IκB-α
IKK
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
HERDC Pre-Audit
Admin Only - UQCCR
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 09 Oct 2016, 10:16:17 EST by System User on behalf of UQ Centre for Clinical Research